Relationship between the intratumor pharmacokinetics and antitumor effect of the payload eribulin in the novel antibody-drug conjugate MORAb-202

被引：0
|
作者：
Koganemaru, S. [1 ]
Fuchigami, H. [2 ]
Tsugawa, H. [2 ]
Kuboki, Y. [1 ]
Furuuchi, K. [3 ]
Uenaka, T. [3 ]
Doi, T. [1 ]
Yasunaga, M. [2 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[3] Eisai Inc, Epochal Precis Anticanc Therapeut EPAT, Exton, PA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
242
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [1] Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models
    Furuuchi, Keiji
    Rybinski, Katherine
    Fulmer, James
    Moriyama, Tomoyuki
    Drozdowski, Brian
    Soto, Allis
    Fernando, Shawn
    Wilson, Kerrianne
    Milinichik, Andrew
    Dula, Mary Lou
    Tanaka, Keigo
    Cheng, Xin
    Albone, Earl
    Uenaka, Toshimitsu
    CANCER SCIENCE, 2021, 112 (06) : 2467 - 2480
  • [2] MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
    Cheng, Xin
    Li, Jing
    Tanaka, Keigo
    Majumder, Utpal
    Milinichik, Andrew Z.
    Verdi, Arielle C.
    Maddage, Christopher J.
    Rybinski, Katherine A.
    Fernando, Shawn
    Fernando, Danielle
    Kuc, Megan
    Furuuchi, Keiji
    Fang, Frank
    Uenaka, Toshimitsu
    Grasso, Luigi
    Albone, Earl F.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) : 2665 - 2675
  • [3] MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts
    Rybinski, Katherine A.
    Maddage, Christopher
    Cheng, Xin
    Albone, Earl
    Grasso, Luigi
    Furuuchi, Keiji
    Uenaka, Toshimitsu
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [4] Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells
    Matsunaga, Yuki
    Yamaoka, Toshimitsu
    Ohba, Motoi
    Miura, Sakiko
    Masuda, Hiroko
    Sangai, Takafumi
    Takimoto, Masafumi
    Nakamura, Seigo
    Tsurutani, Junji
    ANTIBODIES, 2021, 10 (01) : 1 - 18
  • [5] First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors
    Shimizu, Toshio
    Fujiwara, Yutaka
    Yonemori, Kan
    Koyama, Takafumi
    Sato, Jun
    Tamura, Kenji
    Shimomura, Akihiko
    Ikezawa, Hiroki
    Nomoto, Maiko
    Furuuchi, Keiji
    Nakajima, Ryo
    Miura, Takuma
    Yamamoto, Noboru
    CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3905 - 3915
  • [6] MORAb-202, a folate receptor-alpha (FRA)-targeting antibody-eribulin drug conjugate (ADC), exhibits durable antitumor activity and payload-mediated bystander effects on the tumor microenvironment in triple-negative breast cancer
    Furuuchi, Keiji
    Cheng, Xin
    Rybinski, Katherine
    Moriyama, Tomoyuki
    Fulmer, James
    Maddage, Chris
    Milinichik, Andrew
    Tanaka, Keigo
    Lai, George
    Dula, Mary Lou
    Fernando, Danielle
    Grasso, Luigi
    Albone, Earl
    Uenaka, Toshimitsu
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors
    Mignard, Caroline
    Durix, Coralie
    Rybinski, Katherine
    Cheng, Xin
    Furuuchi, Keiji
    Albone, Earl
    Uenaka, Toshimitsu
    de Boisferon, Marc Hillairet
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Preclinical testing of farletuzumab ecteribulin (FZEC [MORAb-202]) and MORAb-109, folate receptor α and mesothelin targeting antibody-drug conjugates (ADCs), in rare gynecologic cancers
    Vandenberg, Cassandra J.
    Rybinski, Katherine
    Nesic, Ksenija
    Lim, Ratana
    Neagle, Chloe
    Ho, Gwo-Yaw
    Ratnayake, Gayanie
    Papenfuss, Anthony T.
    Furuuchi, Keiji
    Barker, Holly E.
    Scott, Clare L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload
    Smith, Sean W.
    Jammalamadaka, Vasu
    Borkin, Dmitry
    Zhu, Jianyu
    Degrado, Sylvia J.
    Lu, Jennifer
    Huang, Jianqing
    Jiang, Ying-Ping
    Jain, Nareshkumar
    Junutula, Jagath R.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (01): : 56 - 60
  • [10] Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX
    de Boisferon, Marc Hillairet
    Mignard, Caroline
    Durix, Coralie
    Uenaka, Toshimitsu
    Rybinski, Katherine
    Cheng, Xin
    Furuuchi, Keiji
    Albone, Eart
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345